Skip to main content
Delfa

← All trials/NCT07734870

RecruitingPhase 2

Tirzepatide for Treatment of CCCA

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

2

Recruiting sites

2

Estimated enrollment

20

Study population

Prediabetes / glucose intolerance

Eligibility highlights

-

Primary endpoints

•Central Centrifugal Cicatricial Alopecia Clinical Activity Tool Score•Scalp Gene-Expression Profiles

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07734870
Org study IDIRB00543694

Timeline

Milestones

Study first posted2026-07-29actual
Study start2026-09-15actual
Last update posted2026-11-03actual
Primary completion2028-05-25estimated
Study completion2028-05-25estimated

Assets

Investigational agents

Tirzepatide

Who this study enrolls

Prediabetes / glucose intolerance

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Age 18 to 80 years.
•Clinical and/or biopsy-confirmed diagnosis of central centrifugal cicatricial alopecia (CCCA).
•Active CCCA, defined as a C-CAT disease activity score greater than 1.
•No treatment for CCCA during the 6 weeks before enrollment.
•Able and willing to complete the study and follow all study procedures.
•Managed by a Johns Hopkins dermatologist throughout the study.

Exclusion criteria

•Currently taking an oral or systemic blood glucose-lowering medication.
•Currently taking another medication for weight loss.
•Hemoglobin A1C below 5.4%.
•Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) score below 2.
•Body mass index below 19 kg/m².
•Pregnant, breastfeeding, or planning a pregnancy.
•Personal or family history of medullary thyroid cancer.
•Personal or family history of multiple endocrine neoplasia type 2.
•History of chronic kidney disease.
•History of pancreatitis.
•History of diabetic retinopathy.
•Severe gastrointestinal disease.
•Recent or planned major surgery.
•Type 1 diabetes.
•Any other contraindication to tirzepatide.
•History of keloids or hypertrophic scarring.
•History of poor wound healing.
•History of a blood-clotting disorder.
•Allergy to lidocaine or epinephrine.
•Known sensitivity to local numbing medication.
•Any significant medical condition that the investigator believes would make participation unsafe or prevent completion of the study.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other (unclassified)

4 endpoints
Primary/protocol endpoint/low confidence

Change in Central Centrifugal Cicatricial Alopecia Clinical Activity Tool Score

Time frame:Baseline, 3 months, 6 months

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in Scalp Gene-Expression Profiles

Time frame:Baseline, 6 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Change in Central Hair Loss Grade

Time frame:Baseline, 3 months, 6 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Physician Global Assessment of Change in Hair Loss

Time frame:Baseline, 3 months, 6 months

change from baseline, improvement

Publications (9)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateNovember 5, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.